Lin Lai

机构：Zhejiang Chinese Medical University, NetApp (United States), National Medical Products Administration, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture · ORCID：0000-0001-8752-3725

发表论文 34 篇 · 总被引 288 次 · h-index 11

代表论文

• Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study (2021 · Radiation Oncology · 被引 65)
• Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib (2021 · Medicine · 被引 24)
• Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: A meta-analysis (2022 · PLoS ONE · 被引 22)
• Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis (2021 · Frontiers in Oncology · 被引 20)
• Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis (2021 · Frontiers in Oncology · 被引 18)
• Selenium hyperaccumulator plant Cardamine enshiensis: from discovery to application (2023 · Environmental Geochemistry and Health · 被引 14)